[ascct] Fwd: CAATwalk: News and Updates

  • From: Kristie Sullivan <KSullivan@xxxxxxxx>
  • To: "ascct@xxxxxxxxxxxxx" <ascct@xxxxxxxxxxxxx>
  • Date: Wed, 6 Feb 2013 16:33:31 -0500

Dear Colleagues,

Please see below for the latest upcoming events from CAAT. You can see a web 
version of the newsletter here:


Kristie Sullivan
Secretary, ASCCT

Begin forwarded message:

From: Center for Alternatives to Animal Testing (CAAT) 
Subject: CAATwalk: News and Updates
Date: February 6, 2013 12:56:20 PM PST
Reply-To: Center for Alternatives to Animal Testing (CAAT) 

Updates from the Center for Alternatives to Animal Testing (CAAT)

Email not displaying correctly?
View it in your 


CAATwalk       February 6, 2013

February brings with it this year's call for proposals for CAAT's 2014-2015 
grants, along with announcements of several important meetings. If you plan to 
attend, please be sure to add them to your calendar and make travel 
arrangements soon. And as always, feel free to forward this newsletter to your 

Satellite Meeting at Society of Toxicology (SOT): Updates on 21st Century 
Toxicology Activities and Related Efforts
Thursday, March 14, 2013 (Immediately after SOT ends)
12:30pm - 4pm
San Antonio, Texas
Grand Hyatt Presidio Room
Presented by CAAT
This meeting will provide a forum for interested stakeholders to update each 
other on efforts to advance pathway-based approaches to toxicology, as 
exemplified by the 2007 National Research Council report on “Toxicity Testing 
in the 21st Century” (“TT21C”). The meeting also will address efforts to 
promote the use of systematic reviews and related evidence-based approaches in 
toxicology, with an emphasis on their relevance to TT21C.

Full SOT 2013 


12:30  Box lunch and Welcome, Thomas Hartung (Johns Hopkins University)

13:00  Invited Presentations (10 minutes each plus 5 minutes for discussion)

 *   David Dix (US Environmental Protection Agency) – ToxCast Update
 *   Raymond Tice (US National Institute of Environmental Health Science) – 
Tox21 Update
 *   Russell Thomas (Hamner Institutes for Biomedical Sciences) – Hamner 
TT21C-related Activity Update
 *   Thomas Hartung (Johns Hopkins) – The Center for Alternatives to Animal 
Testing’s TT21C-related Activity Update
 *   Richard Judson (US EPA) – Validation of High-throughput Assays
 *   Martin Stephens (Johns Hopkins) – Evidence-based Toxicology Update

14:30  Open microphone for additional presentations and discussion

16:00  Adjourn

Questions? Please contact Marilyn 
EU Science: Global Challenges and Global Cooperation
March 4-8, 2013
European Parliament, Brussels
Details and 


March 7th: New Regulatory Science in Systems Toxicology
UPDATE ON THE KNOWLEDGE or PARADIGM SHIFT? Panel Discussion and Audience 

 *   Thomas Hartung- Director, Center for Alternatives to Animal Testing (CAAT)
 *   Emily McIvor– HSI
 *   Donald Prater– FDA
 *   Adrianno Henney– VIRTUAL LIVER
 *   Rex Fitzgerald– SCAHT
 *   Robert Barouki – INSERM
 *   Francois Busquet– CAAT EUROPE– as MODERATOR

Worldwide Implementation of the 3Rs in Regulatory Toxicology: What are the 
Leadership Challenges and Opportunities?
Panel Discussion and Presentations

 *   3Rs Implementation in North America
Paul Locke- Policy Program Director, Center for Alternatives to Animal Testing 

 *   3Rs Implementation in Latin America
Octavio Presgrave- BraCVAM

 *   3Rs Implementation in the EU
Björn Hansen- EC

 *   3Rs Implementation in Japan, India, China, and Korea (Pacific Basin)
Richard Fosse- GSK

 *   3Rs Implementation in Australia
Brett Lidbury- Australian National University

 *   Final Presentation: 3Rs Wrap-up and Summary What We Have Learned Today on 
the State of the Implementation of the 3Rs
Joyce Tischler– Animal Legal Defense Fund

Workshop: Lessons Learned, Challenges, and Opportunities: The US Endocrine 
Disruptor Screening Program
April 23-24, 2013, Research Triangle Park, NC
This workshop brings together multiple stakeholders including CAAT as 
co-organizer in an open forum to review and discuss the challenges and lessons 
learned from the initial experiences with Tier 1 screening assays. This open 
meeting, with all stakeholders—including Federal Regulatory Agencies, NGOs, 
industry, contract laboratory scientists, and academic researchers—is critical, 
and timely, to utilize the collective experience for potential improvements in 
Tier 1 assays and to further advance endocrine disruption assessment. All 
stakeholders and interested parties are invited to participate.

Information and Registration: 
Clinical Trial and Error: Beauty and the Beast
February 15, 2013, Boston, MA
Hynes Convention Center, Room 309
At the AAAS 2013 Annual Meeting
Independent clinical trials are fundamental to improving the results, safety, 
and cost-effectiveness of health care. Because of costs, the scope of these 
trials is often limited to new products. Important clinical interventions, 
surgery, physiotherapy, and rehabilitation are of less interest to commercial 
sponsors seeking primarily drug and device authorization. Whereas 
investigator-driven studies now find support in the United States and European 
Union, they cannot match the resources available for commercial clinical 
trials. Public and charitable funding typically backs health care–orientated 
trials independently of manufacturers, but is often much smaller in size. 
Results matter. When we do get such new evidence, it allows us to look back: 
how good was the preclinical research to start with? While evidence-based 
medicine is the health care imperative of the 21st century, it remains 
difficult to generate the evidence base for pressing public health challenges. 
This session unites key stages and world authorities in the clinical trials 
process to explain why and what must change. With expertise on leading animal 
and human studies to end products, speakers will provide new insights into how 
clinical trials are conducted. Their common cause will be to argue that greater 
international cooperation and standards are required. That said, effective 
communication of clinical and societal benefits must be better coordinated to 
citizens, patients, health-care professionals, researchers, policy-makers, and 
society as a whole.

Organizer: Aidan Gilligan (Irish), Founder, CEO of SciCom - Making Sense of 
Science; Contact: ag@xxxxxxxxxx<mailto:ag@xxxxxxxxxx>

Moderator: Dr Klaus Bock (Danish), Champion Euroscience Open Forum 2014 
Copenhagen, Member of the European Research Council’s Scientific Council


 *   Professor Anne Glover, (British), Chief Scientific Adviser to European 
Commission President, José Manuel Barroso
 *   Wilson M. Compton, (USA), M.D., M.P.E., Director, Division of 
Epidemiology, Services and Prevention Research, National Institute on Drug 
Abuse, National Institutes of Health, U.S. Department of Health and Human 


 *   Dr. Thomas Hartung (German), Professor and Chair for Evidence-based 
Toxicology, Director, Center for Alternatives to Animal Testing, Johns Hopkins 
University, Bloomberg School of Public Health, Dept. of Environmental Health 
Look back in anger? What clinical trials tell us about pre-clinical 
 *   Jay Siegel (American), Chief Biotechnology Officer for Johnson & Johnson & 
Head of Pharmaceutical Global Regulatory Affairs for Janssen, Janssen Research 
& Development
Product-orientated versus healthcare-orientated clinical trials
 *   Dr. Paul J. Kenny (Irish), Associate Professor, Laboratory of Behavioral 
and Molecular Neuroscience, Department of Molecular Therapeutics, The Scripps 
Research Institute - Florida
The latest clinical trial research on brain reward systems

Registration and 

Best wishes from all of us,

The CAAT Team

CAAT Grants Program: Call for Preproposals
Deadline: March 22, 2013

The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) is 
soliciting projects that focus on the implementation of the NAS Report: 
Toxicity Testing in the 21st Century: A Vision and a Strategy in the following 

Proposals Relating to Toxicology: Maximum grant amount is $25,000 per year. 
Projects should be developed to provide understanding of mechanism/mode of 
action and to consider how one would be able to translate the mechanism to a 
method that can be used to evaluate/predict health consequences.

To apply for a CAAT grant, complete the preproposal form 
 and return so that the submission reaches us no later than March 22, 2013.
Full details on CAAT's grant program may be found 

follow on 
 | friend on 
 | forward to a 

Copyright © 2013 Johns Hopkins Center for Alternatives to Animal Testing, All 
rights reserved.
You are receiving this email as a friend or colleague of CAAT.

US Office: 615 N. Wolfe St. W7032 • Baltimore, MD 21205
Phone: 410-614-4990 • Fax: 410-614-2871

European Office: University of Konstanz
POB 600 78457 Konstanz, Germany
Phone: +49-531-882233 • Fax: +49-7531-884156

unsubscribe from this 
 | update subscription 

Other related posts: